RAB9B, member RAS oncogene familyGenealiases: RAB9L · Rab-9L
Q-omics provides the consensus-scored RAB9B profile across patient tissues and cancer cell-line models. RAB9B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, RAB9B is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, RAB9B RNA expression shows 19,874 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, BLCA, and UVM as cancer lineages where RAB9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB9B survival associations across molecular data types. RAB9B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB9B RNA expression–survival associations across cancer types. High RAB9B expression shows unfavorable associations in UCEC and LUSC, but favorable associations in LGG, LUAD, PAAD and ACC. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for RAB9B RNA expression.
This table summarizes RAB9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB9B shows lower tumor expression in BLCA, COAD, KICH and UCEC and higher tumor expression in KIRC and KIRP. The BLCA box plot shows higher RAB9B RNA expression in normal versus tumor tissue (log2 FC = −4.275, t-test p < 0.001).
This table shows molecular features associated with RAB9B in patient tissues and cancer cell lines. In patient samples, RAB9B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUSC.
